TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23327033

Group type: COMPARATOR
Intervention: Esmolol infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion
Number of subjects: 20
Study: 20350344

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplemented parenteral nutrition (PN)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard olive oil (OO) emulsion
Number of subjects: 27
Study: 19104986

Group type: EXPERIMENTAL
Intervention: 30-day momentary assessment protocol of pain and fatigue
Number of subjects: 105
Study: 16129793

Group type: EXPERIMENTAL
Intervention: Filter-wire group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 12375752

Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 104
Study: 10474757

Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m2 or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin-vinorelbine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 0
Study: 8866910

Group type: EXPERIMENTAL
Intervention: Comprehensive multiple risk factor modification programme
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study: 1983321

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg o.m.)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ranitidine (300 mg b.d.)
Number of subjects: 98
Study: 7025257

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 8
Study: 30391468

Group type: EXPERIMENTAL
Intervention: Step-up approach
Number of subjects: 73

Group type: COMPARATOR
Intervention: Open necrosectomy
Number of subjects: 73
Study: 28340570

Group type: EXPERIMENTAL
Intervention: Vacc-C5 vaccine administered intramuscularly with Alhydrogel or intradermally with GM-CSF as adjuvant
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vacc-C5 vaccine
Number of subjects: 36
Study: 25590334

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring system (RT-CGMS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intermittent capillary glucose testing (IGM)
Number of subjects: 48
Study: 24025012

Group type: EXPERIMENTAL
Intervention: Adductor tenotomy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined adductor tenotomy and hernioplasty
Number of subjects: 155
Study: 21872212

Group type: EXPERIMENTAL
Intervention: Surgical repair of AVSD
Number of subjects: 215
Study: 19017864

Group type: EXPERIMENTAL
Intervention: Prophylactic nasal continuous positive airway pressure (nCPAP) at 10 cm H(2)O for at least 6 hours
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard treatment including 10 min of intermittent nCPAP at 10 cm H(2)O every 4 hours
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prophylactic nasal continuous positive airway pressure (nCPAP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 500
Study: 17237648

Group type: COMPARATOR
Intervention: Conventional MUF (group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High flow rate MUF (group H)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High negative pressure MUF (group P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Long duration, high flow rate MUF (group L)
Number of subjects: 80
Study: 14725516

Group type: EXPERIMENTAL
Intervention: Synacthen Depot 1 mg (1 ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.9% saline 1 ml
Number of subjects: 18
Study: 11467465

Group type: EXPERIMENTAL
Intervention: Pacemaker telemetry
Number of subjects: 18

Group type: COMPARATOR
Intervention: Holter recordings
Number of subjects: 18
Study: 9720545

Group type: EXPERIMENTAL
Intervention: Topical urethral anesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical urethral anesthesia with adjunctive intravenous sedoanalgesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (Topical anesthesia and Sedoanalgesia)
Number of subjects: 45
Study: 8158032

Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis (10 mg/kg initial loading dose)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis
Number of subjects: 339

Group type: COMPARATOR
Intervention: Falciparum malaria
Number of subjects: 339

Group type: COMPARATOR
Intervention: Maternal anemia at delivery (hematocrit < 30%)
Number of subjects: 339
Study: 3377147

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular papaveretum 0.2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: No medication (placebo)
Number of subjects: 60
Study: 31131641

Group type: EXPERIMENTAL
Intervention: Supported group (physiotherapist-supported individualised activity programme)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unsupported group (free choice, control)
Number of subjects: 30
Study: 29553862

Group type: EXPERIMENTAL
Intervention: mpHBV SC
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: mpHBV IM
Number of subjects: 722

Group type: COMPARATOR
Intervention: Heptavax®‐II SC
Number of subjects: 722
Study: 27893482

Group type: EXPERIMENTAL
Intervention: Weighted Vest (WV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unresisted Sprint (US)
Number of subjects: 19
Study: 26679936

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the right DLPFC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left DLPFC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left DLPFC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the right DLPFC
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study: 23446073

Group type: EXPERIMENTAL
Intervention: Biofeedback-based cognitive-behavioral treatment (BFB-CBT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 58
Study: 22010417

Group type: EXPERIMENTAL
Intervention: Spiramycin for 7 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study: 18398800

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 0
Study: 17353630

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) every three weeks (TC) for 4 cycles
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) every three weeks (TC) for 8 cycles
Number of subjects: 8
Study: 14576955

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 4875

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 4875
Study: 11507921

Group type: EXPERIMENTAL
Intervention: Experimental triclosan-containing dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice
Number of subjects: 0
Study: 9773111

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem (300 mg)
Number of subjects: 0
Study: 8196120

Group type: EXPERIMENTAL
Intervention: OspA Lyme vaccine (10 micrograms, 2 doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OspA Lyme vaccine adsorbed to alum (10 micrograms, 2 doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Buffer placebo
Number of subjects: 36
Study: 3281563

Group type: EXPERIMENTAL
Intervention: Portal disconnection of the esophagus with a clip (surgical group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical treatment (control group)
Number of subjects: 100
Study: 31690121

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with 1% lidocaine and epinephrine (1 mL, 40 mg triamcinolone + 1 mL lidocaine with epinephrine)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Corticosteroid injection with normal saline (1 mL, 40 mg triamcinolone + 1 mL normal saline)
Number of subjects: 73
Study: 30199771

Group type: EXPERIMENTAL
Intervention: Online expanded Body Project (n=46)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Assessment-only control condition (n=36)
Number of subjects: 82
Study: 27106967

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 4 g over 1 h, then 1 g per h over six h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-haemorrhagic group (NH)
Number of subjects: 0
Study: 24504445

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 45 mg/m² every 4 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Capecitabine 1000 mg/m² twice daily, day 1-14 every 3 weeks
Number of subjects: 78
Study: 22776045

Group type: EXPERIMENTAL
Intervention: CC with a bolus calculator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual CC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (traditional dietary education)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 20660038

Group type: EXPERIMENTAL
Intervention: 1 μg cosyntropin test
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 56
Study: 18486512

Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels of 17-22 mg/dl
Number of subjects: 3989

Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels of 23-38 mg/dl
Number of subjects: 3989

Group type: EXPERIMENTAL
Intervention: Baseline alanine aminotransferase (ALT) levels greater than 38 mg/dl
Number of subjects: 3989

Group type: COMPARATOR
Intervention: Baseline alanine aminotransferase (ALT) levels
Number of subjects: 3989
Study: 16133900

Group type: EXPERIMENTAL
Intervention: Project SPORT (brief consultation and prescription with a mailed reinforcing follow-up flyer)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Minimal intervention control (wellness brochure and pamphlet about teen health and fitness)
Number of subjects: 604
Study: 12471182

Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg/2 mL) administered into the lumen of the central venous catheter, with a maximum of two doses allowed to dwell for up to 120 minutes each.
Number of subjects: 1064
Study: 9972770

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 7593523

Group type: EXPERIMENTAL
Intervention: GnRH agonist administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone secretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance index > 0.79 before HMG commencement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of RI value 2 days before HMG commencement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregnancy rates
Number of subjects: 0
Study: 2106087

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 4 mg i.v. administered 3 h before GHRH
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 8 mg p.o. administered 12 h before GHRH
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 22 mg p.o. over 2 days before GHRH
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 4 mg i.v. given 3 h before
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 8 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clonidine administration 300 micrograms p.o. with Dex 22 mg
Number of subjects: 34
Study: 388678

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 31375659

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 27470507

Group type: EXPERIMENTAL
Intervention: Virtual unenhanced (VUE) images
Number of subjects: 94
Study: 26115866

Group type: EXPERIMENTAL
Intervention: Highly crosslinked-remelted polyethylene (HXLPE)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Less-crosslinked polyethylene
Number of subjects: 171
Study: 23993403

Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alginate Silver
Number of subjects: 20
Study: 22283110

Group type: EXPERIMENTAL
Intervention: Wheat elimination diet after confirmation of wheat allergy
Number of subjects: 179

Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenge test with wheat flour
Number of subjects: 179
Study: 19415745

Group type: EXPERIMENTAL
Intervention: CYP2C19 (rs4917623) heterozygote carriers
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: AhR (rs2066853) heterozygote carriers
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: ERRG (rs1857407) heterozygote carriers
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: CYP1A2 (rs762551) homozygote carriers
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: CYP2C19 (rs4917623) homozygote carriers
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: ERRG (rs945453) homozygote carriers
Number of subjects: 1067
Study: 17324283

Group type: EXPERIMENTAL
Intervention: Collaborative care approach including contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help
Number of subjects: 126

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Collaborative care approach
Number of subjects: 126
Study: 15607068

Group type: EXPERIMENTAL
Intervention: Changes requested by RECs regarding the Patient Information Sheet (PIS)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: PIS-related features and type of changes requested
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: General content and quality of the PIS
Number of subjects: 187
Study: 11605932

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (10 microg intrathecal sufentanil with or without 2.0 mg bupivacaine, n = 1,071)
Number of subjects: 2183

Group type: COMPARATOR
Intervention: Epidural analgesia (10 microg epidural sufentanil and 12.5-25.0 mg bupivacaine, n = 1,112)
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 2183

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural and epidural analgesia
Number of subjects: 2183
Study: 10921016

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide (CTX) 300 mg/m2, vincristine (VCR) 1.4 mg/m2, adriamycin (ADM) 50 mg/m2, d1; cisplatin (PDD) 20 mg/m2, d1-5, for 4 cycles, followed by oral ftorafur (FT-207) 600-900 mg/d for 1 year
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage III patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery only for stage III patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage I-II patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery only for stage I-II patients
Number of subjects: 70
Study: 8273654

Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (contrast-enhanced MR imaging)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unenhanced MR imaging
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of all sequences (enhanced and unenhanced)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Number of subjects: 60
Study: 2511801

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fleroxacin 600 mg once daily for 7 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg once daily for 7 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fleroxacin (any dosage)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 337916

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Five-drug regimen (vincristine sulfate, prednisone, cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Five-drug regimen after progression of disease
Number of subjects: 72
Study: 31235195

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFEs) + Vocal Hygiene counseling (VH), n=6
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vocal Hygiene counseling (VH), n=4
Number of subjects: 10
Study: 31046941

Group type: EXPERIMENTAL
Intervention: Pitch-earcons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timbre-earcons
Number of subjects: 0
Study: 26869596

Group type: EXPERIMENTAL
Intervention: Passive dynamic wrist and hand orthosis combined with computerised gaming exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional exercises from an exercise book
Number of subjects: 20
Study: 25899102

Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg.d(‐1))
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 25035069

Group type: EXPERIMENTAL
Intervention: SFC 50/250 μg Rotacaps/Rotahaler (S)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SFC 50/250 μg Rotacaps/Rotahaler (L)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SFC 50/100 μg Rotacaps/Rotahaler (L)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SFC at both doses and via both inhalers
Number of subjects: 36
Study: 22915299

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fluence photodynamic therapy (L-PDT) with verteporfin (300 mW/cm² for 83 s, 25 J/cm²)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fluence photodynamic therapy (L-PDT)
Number of subjects: 22
Study: 19306148

Group type: EXPERIMENTAL
Intervention: FearFighter (FF)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clinician-led exposure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Computed-aided relaxation
Number of subjects: 62
Study: 17596474

Group type: EXPERIMENTAL
Intervention: Glyburide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 0
Study: 15049746

Group type: EXPERIMENTAL
Intervention: Cocaine abusers
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heroin abusers
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Alcohol abusers
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heroin abusers (abstinent)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cocaine abusers (abstinent)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Alcohol abusers (abstinent)
Number of subjects: 144
Study: 11282168

Group type: EXPERIMENTAL
Intervention: T cell responses specific for synapsin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Long-term T cell lines specific for synapsin
Number of subjects: 2
Study: 9290271

Group type: EXPERIMENTAL
Intervention: Community-based hypertension control program including blood pressure screening, health education, and follow-up by trained volunteers.
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Community-based hypertension control program targeting hypertensive subjects.
Number of subjects: 897

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 897
Study: 7931475

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 131
Study: 3197711

Group type: EXPERIMENTAL
Intervention: Mitogen stimulation assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled studies using animal lymphocytes or paired human samples
Number of subjects: 0
Study: 29797907

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen needles therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26975954

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 2 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no agent)
Number of subjects: 80
Study: 26291564

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURPb)
Number of subjects: 120
Study: 23902782

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg/d during pregnancy)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 21903984

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 18239086

Group type: EXPERIMENTAL
Intervention: R-HDS (rituximab-supplemented high-dose sequential chemotherapy with autografting)
Number of subjects: 136

Group type: COMPARATOR
Intervention: CHOP-R (6 courses of CHOP followed by rituximab)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Salvage R-HDS after CHOP-R failure
Number of subjects: 136
Study: 16639669

Group type: EXPERIMENTAL
Intervention: Laser scanning tomography (LST) and nerve fibre polarimetry measurements in eyes with large cups
Number of subjects: 117

Group type: COMPARATOR
Intervention: Laser scanning tomography (LST) and nerve fibre polarimetry measurements in normal eyes
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HRT and GDx measurements in eyes with large cups
Number of subjects: 117
Study: 12748567

Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (CRM)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination of CRM and vestibular rehabilitation (VR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 47
Study: 15135713

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0